{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-010148","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.050495+00:00","generated_at":"2026-05-27T01:46:30.088016+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics updates on GT-02287 Phase 1b trial for Parkinson's disease","bullets":["Phase 1b trial of GT-02287 approved; dosing imminent in Australia, enrolling 15-20 patients with GBA1 or idiopathic PD.","Prior healthy volunteer study showed 53% increase in GCase activity and confirmed safety/tolerability.","Cash of $12M as of September 30, 2024, expected to fund operations through interim analysis in 2Q 2025.","FDA pre-IND meeting found no significant regulatory hurdles; IND submission on track for Phase 2 planning in 2H 2025.","Promotion of Gianluca Fuggetta to SVP Finance; company exploring licensing partners and financing options."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-010148","json":"https://secwatch.observer/filing/0001104659-25-010148.json","markdown":"https://secwatch.observer/filing/0001104659-25-010148.md","text":"https://secwatch.observer/filing/0001104659-25-010148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925010148/0001104659-25-010148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925010148/tm255679d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:46:30.088016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}